Crizotinib versus chemotherapy in advanced ALK-positive lung cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyridines

abstract

  • Crizotinib is superior to standard chemotherapy in patients with previously treated, advanced non-small-cell lung cancer with ALK rearrangement. (Funded by Pfizer; ClinicalTrials.gov number, NCT00932893.).

publication date

  • June 24, 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1214886

PubMed ID

  • 23724913

Additional Document Info

start page

  • 2385

end page

  • 94

volume

  • 368

number

  • 25